Ablation devices are at present used in varied healthcare areas such as orthopedic, dermatology, cardiology, gynecology, neurology and several others. Global growth in preference for minimally invasive procedures is helping drive the demand for ablation devices. Major factors supporting the rise in ablation treatments include groping preference from senescent patients andhigh prevalence of chronic diseases.
This report on hematopoietic stem cells transplantation market studies various transplant types and applications. Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases.
This report on global breast cancer treatment market studies various drugs used for treatment of breast cancer along with pipeline analysis of upcoming potential drugs. Breast cancer is the second most common cancer observed in women worldwide, accounting for around 17% of all female cancers, making the disease exceptionally prevalent. The predictions shared by GLOBOCON in 2012 suggests that the incidence rate of breast cancer in 2012 was for ages= 65 was 503, 158 and by 2020 it is anticipated that ages=65 will be 643,442.
Growth in incidence of rectal, GI and colon cancer and flourishing trend of cancer screening through genetic testing are the prime factors allowing the growth of in vitro colorectal cancer screening market. Favorable government guidelines and regulation for increasing awareness in the general population and supporting the adoption colon cancer screening also facilitate the global demand for minimally invasive screening tests that use genetic biomarkers and DNA for risk determination.
Home Healthcare Market is Expected to Grow at 6.5% by 2033. Older adults are majorly benefited with home healthcare as it helps them to stay independently for as long as possible in an injury or illness. Home healthcare covers a broad range of services and can possess capability of delaying the need for long-term nursing home care. According to market experts, in the U.S. currently 12 million patients and more than 428 million patient visits each year out of which 70% are using home healthcare services aged 65 and older.
Biopreservation Market is Expected to Grow at 9.5% by 2033. The process of applying natural or controlled antimicrobials to preserve food materials for extending its shelf life is known as biopreservation. The biopreservation process is usually carried out with the help of lactic acid bacteria (LAB) as they are inhibitory to microbes responsible for food spoilage. The key agents applied in biopreservation process are lactic acid bacteria, yeast, and bacteriophages.
Biomarker based diagnostics have already offered great advanced in the past decade in the field of cancer diagnosis, prognosis, staging and therapy selection. However, tissue-based detection approach produces a major drawback in terms of invasion for sample collection.
Pain management is a branch of medical science which eases the suffering of the patients who have chronic pain. Acute pain has sudden onset of action whereas chronic pain usually lingers for a longer duration which causes unpleasant aggravation in patients which leads to need for its management. Various devices are used to manage chronic pain like Electrostimulation devices, Radiofrequency ablation devices, Infusion pumps and Neurostimulation devices. These devices block the pain gate mechanism to block the passage of pain signals to the brain.
The pharmacovigilance (phv) market is anticipated to grow at a compound annual growth rate of 13.5% for the forecasted period (2025 – 2033). As the world's population ages, chronic diseases have increased; and more adverse drug reactions mean more pharmacovigilance.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.